Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leavitt Defends Bush’s Flu Pandemic Preparedness Plan To Senate

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS will subsidize about 25% of states’ antiviral costs, leading senators to question whether preparedness in some states could suffer.

You may also be interested in...



Democrats Blast HHS For Flu Antiviral Production Shortcomings

Democratic members of the House Government Reform Committee question why HHS Secretary Leavitt has not issue a compulsory license to allow other manufacturers to produce Roche's Tamiflu.

Democrats Blast HHS For Flu Antiviral Production Shortcomings

Democratic members of the House Government Reform Committee question why HHS Secretary Leavitt has not issue a compulsory license to allow other manufacturers to produce Roche's Tamiflu.

Roche Increases Tamiflu Manufacturing Capacity In Time For 2006 Season

President Bush will request $7.1 bil. for pandemic avian flu preparedness, $1 bil. of which will be earmarked for antiviral stockpiling.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS061290

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel